5 April 2019 in Science Advances
Super-resolution fluorescence imaging reveals a previously unknown novel structure of spectrin in inner ear hair cells.
3 October 2023 in Neuroscience Bulletin
Hearing loss has become increasingly prevalent and causes considerable disability, thus gravely burdening the global economy. Irreversible loss of hair cells is a main cause of sensorineural hearing loss, and currently, the only relatively effective clinical treatments are limited to digital hearing equipment like cochlear implants and hearing aids, but these are of limited benefit in patients. It is therefore urgent to understand the mechanisms of damage repair in order to develop new neuroprotective strategies. At present, how to promote the regeneration of functional hair cells is a key scientific question in the field of hearing research. Multiple signaling pathways and transcriptional factors trigger the activation of hair cell progenitors and ensure the maturation of newborn hair cells, and in this article, we first review the principal mechanisms underlying hair cell reproduction. We then further discuss therapeutic strategies involving the co-regulation of multiple signaling pathways in order to induce effective functional hair cell regeneration after degeneration, and we summarize current achievements in hair cell regeneration. Lastly, we discuss potential future approaches, such as small molecule drugs and gene therapy, which might be applied for regenerating functional hair cells in the clinic.
22 March 2025 in Molecular Therapy
Pathogenic mutations in the Gjb2 gene, encoding connexin 26, are the leading cause of autosomal-recessive hereditary deafness. Gene therapy holds significant promise for treating this. Adeno-associated virus (AAV) mediated therapeutic gene delivery has been shown to be safe and effective in restoring hearing in both animal models and human patients. However, Gjb2 gene therapy has been hindered by the limited specificity and efficiency of the available AAV vectors. In this study, we screened AAV serotypes and found that co-administration of AAV1 and AAV-ie could effectively target Gjb2-expressing cells. However, the ectopic Gjb2 expression in hair cells induced by these AAVs could cause ototoxicity, which was addressed by employing the specific promoter SCpro. Co-injection of AAV1 and AAV-ie carrying exogenous Gjb2 driven by SCpro effectively restored hearing function in Gjb2-deficient mice. Moreover, the combined AAV system can transduce the cochleae of Bama miniature pigs and AAV administration into the inner ear of cynomolgus monkeys did not impair hearing and showed negligible systemic toxicity, indicating the efficiency and safety of this gene therapy in large animals. Thus, this study provides a strategy for Gjb2 gene therapy and lays a foundation for future clinical applications.
9 September 2025 in Nature Aging
23 September 2025 in Advanced Science
Gene therapy has recently restored natural audibility in humans with OTOF‐gene mutations. This biological restoration of hearing is different from cochlear implantation (CI) that produces artificial hearing via electric stimulation of the auditory nerve. In three published trials, 21 DFNB9 patients show 244 grade I/II adverse events (AEs), 2 grade III AEs and no serious AEs. The average gene therapy effect is substantial (52.4‐dB improvement from baseline complete deafness), rapid (0.74‐month time constant), and stable over the initial six months. However, individual outcomes vary from restored normal audibility (≤20 dB HL) to severe hearing loss (≥80 dB HL). Here critical knowledge gaps in gene therapy are identified such as understanding the individual variability, assessing temporal processing, and comparing efficacy with cochlear implantation. It is predicted that gene therapy will include patients with less than complete hearing loss and target other monogenic forms of congenital deafness. Advanced technologies in minimally invasive drug delivery and gene editing will further increase the safety, efficacy and applicability of gene therapy for hearing loss. Cochlear implantation likely remains the standard intervention for severe‐to‐profound hearing loss, but gene therapy will emerge as a viable alternative in treating monogenic forms of deafness.
17 November 2024 in Molecular Therapy Nucleic Acids
Inner ear hair cell (HC) damage is irreversible in mammals, but it has been shown that supporting cells (SCs) have the potential to differentiate into HCs. Serpine2, a serine protease inhibitor, encodes protease nexin 1, and this has been suggested to be a factor that promotes HC regeneration. In this study, we overexpressed Serpine2 in inner ear SCs cultured in two- and three-dimensional systems using the adeno-associated virus-inner ear (AAV-ie) vector, which promoted organoid expansion and HC differentiation. Overexpression of Serpine2 in the mouse cochlea through the round window membrane (RWM) injection promoted SC proliferation and HC regeneration, and the regenerated HCs were found to be derived from Lgr5+ SCs. Regenerated HCs have electrophysiological properties that are similar to those of native HCs. Notably, Serpine2 overexpression promoted HC survival and restored hearing of neomycin-damaged mice. In conclusion, our findings indicate that Serpine2 overexpression promotes HC regeneration and suggests that the utilization of inner ear progenitor cells in combination with AAVs might be a promising therapeutic target for hearing restoration.